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Abstract
Use of carbamazepine (CBZ) and oxcarbazepine (OXC) as first line antiepileptic
drugs in the treatment of focal epilepsy is limited by hyponatremia, a known adverse
effect. Hyponatremia occurs in up to half of people taking CBZ or OXC and, although
often assumed to be asymptomatic, it can lead to symptoms ranging from
unsteadiness and mild confusion to seizures and coma. Hyponatremia is probably
due to the antidiuretic properties of CBZ and OXC that are, at least partly, explained
by stimulation of the vasopressin 2 receptor (V2R)/Aquaporin 2 (AQP2) pathway. No
known genetic risk variants for hyponatremia exist, but likely candidate genes are
part of the vasopressin water reabsorption pathway.
Introduction
Trial and error in drug choice is still an important aspect of pharmacotherapy in
epilepsy. Finding an effective anti-epileptic treatment without significant adverse
reactions (ADRs) for an individual may take months to years. Persistent seizures (in
up to one-third of people) and ADRs lead to severe burdens in people with epilepsy,
limiting their quality of life and prospects. The challenge for future
pharmacotherapy is to find optimal treatment with minimal delay.
Pharmacogenomics may be a valuable tool for this, as it aims to uncover genetic
variants that influence drug response in order to individualize a person’s therapy
and improve outcome. The clinical use of pharmacogenomics in epilepsy is well
demonstrated by carbamazepine (CBZ)-induced severe cutaneous reactions. CBZ
causes hypersensitivity reactions in up to 10% of people, ranging from mild to the
life-threatening Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis
(TEN). In 2004 it was found that HLA-B*1502 was strongly associated with CBZ-
induced SJS/TEN in the Han-Chinese population, increasing the risk about 100 fold.
(1) In Caucasian populations, in which the allele frequency of HLA-B*1502 is very
low (<0.1%), an association was found between carbamazepine hypersensitivity and
HLA-A*3103 (allele frequency 2-5%). (2) In the South-East Asian population
screening for HLA-B*1502 prior to CBZ prescription is now routinely performed due
to the relatively high HLA carrier rate (17%). (3)
Another common adverse effect of CBZ and its keto-analogue oxcarbazepine (OXC)
is hyponatremia. Here we review the clinical importance of hyponatremia related to
CBZ and OXC use, the mechanism of the antidiuretic effect and the potential role for
pharmacogenomics in uncovering the genetic predisposing factors.
ANTIEPILEPTIC DRUGS
Carbamazepine was first introduced in 1962. (4) In the central nervous system, CBZ
reduces neuronal hyperexcitability and exerts its action mainly by inhibition of
voltage-gated sodium channels. (5) Fifty years later it is still recommended as a
drug of first choice for treating focal epilepsy despite recent concerns about its
potential to induce liver enzymatic systems. (6-8) Indeed, CBZ is losing ground to
the newer antiepileptic drugs (AEDs) due to these concerns. CBZ is also prescribed
in the treatment of trigeminal neuralgia and bipolar disorders. Frequent ADRs of
CBZ include drowsiness, loss of coordination, vertigo, rash, leucopenia,
osteoporosis, hepatotoxicity and hyponatremia.
OXC, introduced in 1990, was developed as keto-analogue of CBZ to avoid
formation of the epoxide metabolite of CBZ. (9) OXC and CBZ appear to be similarly
effective. In a double-blind study comparing OXC and CBZ in people with newly
diagnosed epilepsy, complete seizure control was achieved in 52% with OXC
treatment and in 60% with CBZ treatment, a non-significant difference. (9) Similarly,
a 50% reduction in seizure frequency was seen in 80% of people taking OXC and 81%
taking CBZ. (9, 10) Subsequent studies showed better tolerability of OXC, apart from
hyponatremia. Several studies have demonstrated that CBZ induces hyponatremia in
5-40 % of individuals. (11, 12) For OXC the incidence appears to be even higher at
30-51%. (12, 13) This serious ADR sometimes results in partial or complete
withdrawal, seriously limiting the use of CBZ and OXC. (14)
THE ADVERSE DRUG RESPONSE
Hyponatremia is defined as a serum sodium level < 136 mEq/l resulting in excess
total body water relative to total solute. It is considered mild when sodium levels
are between 131 and 135 mEq/l, moderate when 125-130 mEq/l and severe when
< 125mEq/l. (15, 16) Acute severe hyponatremia is associated with neurological
symptoms such as seizures and coma and should be treated urgently to prevent
life-threatening complications such as cerebral edema and encephalopathy. (15, 17,
18) Chronic hyponatremia causes more subtle neurological symptoms such as
unsteadiness, difficulty concentrating, reduced attention span, mild confusion and
personality changes. (19, 20) These symptoms are often mistakenly attributed to the
underlying disorder, personality or direct drug toxicity without considering
hyponatremia as a potential cause. The underestimation of symptoms was
demonstrated by a study in 122 individuals with “asymptomatic” chronic
hyponatremia with various causes; 12% were admitted to hospital for falls compared
with 5% in matched controls. (19)
Several risk factors exist for hyponatremia associated with CBZ use, including age >
40 years, concomitant use of other medications associated with hyponatremia (21)
(table 1), menstruation, psychiatric conditions, surgery, (psychogenic) polydipsia
and female gender. (22, 23) Similar risk factors exist for OXC, but age> 40 years is
correlated more strongly, as shown by the higher rate of hyponatremia in people
over 40 years of age taking either OXC (60%) or CBZ (20%). (12) A study of OXC-
induced severe hyponatremia in a large cohort (n=1009) provided further support
for age, concomitant use of diuretics and AED polytherapy as independent risk
factors. (24) There is no clear dose-effect relationship between OXC and occurrence
of hyponatremia. (12) In contrast, for CBZ a negative relationship between plasma
sodium concentration and CBZ serum concentration, as well as the cumulative daily
dose, has been described (25, 26); this could not be confirmed in another study.
(27)
Case
An individual with epilepsy attending our Centre was successfully treated with OXC
for over 10 years. Serum sodium levels were chronically low (121-129 mEq/l) and
mild dizziness was accepted as the cost for complete seizure control. Due to
hypertension, a combination of the ACE-inhibitor perindopril and the thiazide-like
diuretic indapamide was added and the sodium level dropped to 114 mEq/l within a
few days of the start, causing falls, cognitive slowness and hospitalization.
Indapamide was stopped, the sodium level increased to 123 mEq/l and the
symptoms disappeared. This case is an illustration of the care needed when adding
medication associated with hyponatremia in people using CBZ/OXC.
Table 1 Other drugs associated with hyponatremia (21).
Drugs affecting sodium and water homeostasis
Diuretics
incidence
hyponatremia cause
Thiazides and related substances (indapamide) 11%
extracellular volume depletion and syndrome of
inappropriate antidiuretic hormone secretion
(SIADH)
sodium lossOther (amiloride)
Drugs affecting water homeostasis
Increased hypothalamic production of vasopressin
Antidepressants
Tricyclic antidepressants (amitryptiline,
protriptyline, desipramine)
Selective serotonin reuptake inhibitors (SSRIs) 0.5-32%
Monoamine oxidase inhibitors (MAOs)
Antipsychotic drugs SIADH and polydipsia
Phenothiazines (chlorpromazine, fluphenazine) dry mouth
Butyrophenones (haloperidol)
Antiepileptic drugs
sodium valproate
Anticancer agents
Vinca alkaloids (vincristine, vinblastine) neurohypophysis toxicity
Platinum compounds (cisplatin, carboplatin) 43% SIADH and renal salt wasting
Alkylating agents (cyclophosphamide,
melphalan, ifosfamide)
Miscellaneous (methotrexate, interferon α and ɤ, Nausea-induced vasopressin production
levamisole, pentostatin, monoclonal antibodies)
Opiates
Potentiation of vasopressin effect
Antiepileptic drugs
Lamotrigine
Antidiabetic drugs
Sulfonylurea derivatives (chlorpropamide, tolbutamide) 4-6%
Anticancer agents
Alkylating agents (cyclophosphamide) impaired water secretion
Nonsteroidal anti-inflammatory drugs rare
↓renal prostaglandin synthesis (vasopressin
inhibitor)
‘Reset osmostat’ (SIADH variant)
Antidepressants
Venlafaxine
THE MECHANISM
There are several different biological mechanisms that can lead to hyponatremia.
Simplified, there is either too much water (polydipsia, inappropriate antidiuresis) or
too little salt (low intake or salt wasting) present. (16) Hyponatremia related to drugs
is mainly caused by the syndrome of inappropriate antidiuresis (SIAD)(16). An
antidiuretic effect of CBZ was first reported in 1966 when it was found to be
beneficial in people with diabetes insipidus, a disorder characterized by polydipsia
and polyuria caused by a lack of pituitary vasopressin production. (28, 29). In early
case reports of CBZ-induced hyponatremia both elevated (30, 31) and lowered (32)
levels of vasopressin (also called antidiuretic hormone, ADH) were found. These
findings suggested that CBZ either stimulates vasopressin secretion from the
posterior pituitary gland or has a direct renal effect itself. According to the renal
effect theory, CBZ is thought to increase the sensitivity of osmoreceptors to
vasopressin in the renal distal convoluted tubules and collecting ducts or to exert a
direct effect on these receptors leading to water retention. (11) (Fig 1)
A combined central and renal effect has been suggested. (33) In a cross-over study,
water loading tests were performed in 12 healthy volunteers before and after
receiving 600 mg/day CBZ for seven days. With CBZ, vasopressin levels increased
less during water deprivation and decreased less during water loading, without
affecting plasma sodium concentration and plasma osmolality. It was concluded that
osmoreceptors were less responsive as a result of CBZ. (33) Impaired diuresis during
CBZ use was also observed, despite similar vasopressin concentration at peak
diuresis when on and of CBZ. (33) It could be argued that this is a direct effect of
CBZ on receptors in the renal tubules.
For OXC a similar cross-over design study was performed in a group of people with
epilepsy and a group of healthy controls. Exposure to OXC for 3 weeks resulted in
significant reduction in serum osmolality (i.e. hypotonicity) and serum sodium
concentration after a water loading test in both groups. Hypotonic hyponatremia
was not associated with a significant change in serum vasopressin levels, but was
the result of both a relative inability to dilute the urine and a reduction of over 50%
in water excreted after the water loading test. (34)
Vasopressin exerts its antidiuretic action by binding and activating the arginine
vasopressin receptor 2 (V2R), resulting in an increase in intracellular cyclic
adenosine monophosphate (cAMP). cAMP promotes shuttling of intracellular
vesicles, containing Aquaporin 2 (AQP2) water channels, to the apical membrane of
the collecting-duct cells. Water permeability is thereby increased, inducing anti-
diuresis.(35) (36) A rodent study suggested that CBZ could activate the vasopressin
receptor in the renal medulla and that CBZ can induce renal water absorption by
acting directly on the V2R -protein G complex and increasing the AQP2 expression.
In vitro microperfusion experiments showed that CBZ was able to increase water
(re)–absorption in the absence of vasopressin. Tests with selective cAMP and V2R
inhibitors showed that the CBZ effect on water absorption is cAMP-dependent and
acts in the V2R-protein G-complex. In vivo tests were done in 3 groups: controls;
rats on a CBZ diet; and rats initially taking lithium, subsequently taking lithium and
CBZ. The CBZ diet alone did not increase AQP2 expression compared with controls.
CBZ was, however, able to correct nephrogenic diabetes insipidus (NDI) in rats
receiving lithium. Lithium decreases AQP2 expression since it blocks vasopressin
action. Addition of CBZ reversed 20% of the decrease in AQP2 expression. (35)
Paradoxical effects were observed in another rodent study in which CBZ therapy
increased diuresis and electrolyte loss. After rats received the V2R antagonist
savaptan, urinary flow and natriuresis were further increased by CBZ. (37) Thus even
though CBZ has a comparable pharmacological effect to a V2R agonist, some
findings in rat studies suggest that other pathways also play a role.
One pathway of interest is the influence of prostaglandins on water transport.
Prostaglandin E2 (PGE2), a product of arachidonic acid (AA) metabolism by
cyclooxygenase (COX), inhibits vasopressin-induced water permeability by reducing
cAMP levels. (38, 39) (fig 1) Inhibition of PGE2 synthesis potentiates antidiuresis.
Nonsteroidal anti-inflammatory drug-induced hyponatremia has been associated
with the inhibition of synthesis of renal prostaglandins due to COX inhibition. (40)
As well as COX, other enzymes are involved in AA metabolism; lipoxygenase and
cytochrome P450 (CYP450) also metabolize AA. Induction of the CYP450 pathway
results in less AA being available for metabolism by COX, resulting in less renal
prostaglandin synthesis. (41) It is conceivable that CBZ, a major P450-enzyme
inducer, potentiates natriuresis through this mechanism. It is unlikely that this is the
only mechanism as OXC is a weaker CYP450 inducer than CBZ, whereas the
incidence of hyponatremia associated with OXC use seems higher.
Lithium (Li)-induced polyuria due to resistance to vasopressin is mediated by
increased PGE2 signalling acting via P2Y receptors. For CBZ/OXC-induced
hyponatremia this pathway has not yet been assessed. (42, 43)
GENETICS AND PHARMACOGENOMICS
The antidiuretic property of CBZ and OXC seems to be a physiological effect of these
drugs. The fact that hyponatremia is not clearly dose-dependent and is not an
extension of the therapeutic effect suggests an idiosyncratic effect. It is likely that
the severity of the hyponatremia depends on the genetic constitution of the
individual, making subgroups more susceptible. Here we review what is known
about the genetics of the V2R/AQP2 pathway and discuss how this could help us to
learn more about susceptibility to hyponatremia associated with CBZ/OXC use.
X-linked, inactivating mutations in the arginine vasopressin receptor 2 gene (AVPR2)
and autosomal mutations in AQP2 cause nephrogenic diabetes insipidus. (44) From
a pathophysiological perspective the opposite of nephrogenic diabetes insipidus is
nephrogenic syndrome of inappropriate antidiuresis (NSIAD). This was first
described in two unrelated infants and was characterized by excess hypotonic fluid
and undetectable vasopressin levels. (45) Both were hemizygous for an AVPR2
mutation presented with seizures, hyponatremia (123 and 118 mEq/l respectively),
and serum hypo-osmolality with inappropriately elevated urinary osmolality and
sodium levels. Functional studies showed that basal levels of cAMP production in
cells expressing the mutated V2R were four times the levels in cells expressing
wild-type V2R (P=0.01). These AVPR2 mutations created a constitutively active V2R
explaining the hyponatremia with increased urinary osmolality. (45)
After this first NSIAD report, two more families and several sporadic cases have been
described. These families show great variability in phenotype, and NSIAD may go
unrecognized for years. (46, 47) In another described family with five members, two
hemizygous and three heterozygous, were assessed. One hemizygous male
exhibited all the typical NSIAD features. The other four appeared totally
asymptomatic under normal conditions, but all had an abnormal response (including
hyponatremia) when challenged by a mild water load. Persistent excretion of AQP2
independent of vasopressin in four of these five individuals with NSIAD was
consistent with a constitutive V2R activation. (47)
The condition in people with NSIAD is clinically similar to SIAD associated with
CBZ/OXC use. Key characteristics in both are hyponatremia, serum hypo-osmolality,
urine hyper-osmolality, low levels of vasopressin and an abnormal response to a
water loading test. The fact that this genetic condition resembles the effect of CBZ
and OXC use provides some additional support to the findings of a direct action of
these drugs on one of the V2R-dependent pathways. The great variability in
phenotype in people with NSIAD may be explained by interactions with variants in
other genes from these renal pathways. These same variants may also play a role in
the susceptibility to severe hyponatremia during use of CBZ or OXC.
CONCLUSION
Hyponatremia should no longer be considered an asymptomatic condition. (19)
Symptoms such as unsteadiness, dizziness, difficulty concentrating, reduced
attention span, mild confusion, and lethargy in people taking CBZ or OXC should
alert the physician to check the serum sodium level. In people with multiple risk
factors, hyponatremia might occur much faster with more severe, even life
threatening, symptoms. Preventive fluid restriction can be of great value in these
situations.
The mechanism of CBZ/OXC-induced hyponatremia remains incompletely
understood but there is evidence that the antidiuretic effect is, at least partly,
caused by stimulation, direct or via PGE2, of the V2R/AQP2 pathway. In people with
NSIAD serum sodium levels and serum and urine osmolality are changed in the same
direction as that caused by the use of CBZ and OXC. It is possible that other variants
in AVPR2 with influence on the activation state of V2R make people more
susceptible to the antidiuretic effect of CBZ and OXC. Future research should
investigate whether pharmacogenomic risk factors, such as variants in genes from
the vasopressin water reabsorption and the arachidonic acid metabolism pathways,
can identify people at risk of developing clinically relevant hyponatremia induced by
CBZ or OXC. In these people CBZ and OXC should be gradually withdrawn and
alternative antiepileptic drugs should be prescribed. When the person at risk is
dependent on CBZ or OXC for seizure control, electrolytes should be intensively
monitored.
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Fig 1. Vasopressin dependent water regulation. Vasopressin (AVP) acts on V2 receptors (V2R) in the
basolateral plasma membrane. Through the GTP-binding protein Gs, adenylyl cyclase (A.C.) is
activated, stimulating the production of cAMP from ATP. cAMP binds and activates protein kinase A
(PKA), which than phosphorylates AQP2 in intracellular vesicles. AQP2 moves to the apical plasma
membrane to increase water permeability. PGE2 inhibits this process by binding to the Prostaglandin
receptor E3 (EP3)and reducing the production of cAMP. CBZ/OXC influences the water regulation by
activating the V2R/AC complex and/or by inhibiting PGE2 formation.
Appendix
Water loading test: Participants are deprived of water for at least the previous 9 hours (up to 24
hours). The bladder is emptied. A standard water load of 20 ml/kg is given within a period of 30
minutes and urine collected every 15-60 minutes until peak diuresis, usually within 3-4 hours.
The percentage of water load excreted, plasma vasopressin concentration, plasma and urine
osmolality, and serum and urine sodium are measured before and after the water loading test.
In vitro microperfusion: Tubules are dissected from the renal medullas from normal rats and
immersed in a dish of chilled Ringer-HCO3 buffer. After isolation, the segment is transferred to
a temperature-regulated chamber (37°C). The perfusion solution used is a 295±5
mOsmol/kgH2O Ringer-HCO3, and the bath solution is made hypertonic (510±5
mOsmol/kgH2O) by the addition of NaCl. FD&C green dye is added to the perfusate as a visual
marker. Net water absorption was measured with [14C]inulin dialyzed immediately before the
experiments. Isolated inner medullary collecting ducts were perfused in absence of vasopressin
and in the presence of CBZ, in order to determine the osmotic water permeability. Subsequently,
the water permeability was determined in the presence of CBZ + V2R inhibitor and CBZ + cAMP
inhibitor.

